Adaptimmune (ADAP) Down on End of Collaboration With Roche [Yahoo! Finance]
Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.adaptimmune.com/phoenix.zhtml?c=253991&p=irol-newsarticle&id=2255800
Company Research
Source: Yahoo! Finance
Both companies collaborated in 2021 to develop and commercialize allogeneic cell therapies to treat multiple oncology indications. The collaboration had two components — the development of allogeneic T-cell therapies for up to five shared cancer targets and the development of personalized allogeneic T-cell therapies. ADAP was responsible for developing clinical candidates using its induced pluripotent stem cell (iPSC) derived allogeneic platform to produce T-cells (iT cells). Roche was responsible for the input TCRs and subsequent clinical development and commercialization. Adaptimmune received an upfront payment of $150 million and was entitled to additional payments of $150 million over five years, along with milestone payments exceeding $3 billion in aggregate value. The loss of funds from Roche is a setback for ADAP and its investors were clearly disappointed. Shares of Adaptimmune have risen 46.3% year to date against the industry's decline of 7.9%. Image Source: Zac
Show less
Read more
Impact Snapshot
Event Time:
ADAP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADAP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADAP alerts
High impacting Adaptimmune Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ADAP
News
- Global CD70 Targeting Therapies Market & Clinical Trials Report 2024 - Insight by Company, Country, Indication & Phase [Yahoo! Finance]Yahoo! Finance
- Adaptimmune: Huge Opportunity Amid Their Setback With Genentech [Seeking Alpha]Seeking Alpha
- Garry Menzel joins GHO Capital as Operating Partner [Yahoo! Finance]Yahoo! Finance
- Adaptimmune falls as Roche strategic collaboration ends [Seeking Alpha]Seeking Alpha
- Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated [Yahoo! Finance]Yahoo! Finance
ADAP
Sec Filings
- 4/22/24 - Form ARS
- 4/12/24 - Form 8-K
- 4/11/24 - Form DEF
- ADAP's page on the SEC website